Skip to main content
SpringerLink
Log in

Rifabutin prophylaxis against MAC infections

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. N Engl J Med 1993; 329: 898–940

    Article  PubMed  CAS  Google Scholar 

  2. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellular complex in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082–5

    Article  PubMed  CAS  Google Scholar 

  3. Gordin F, Masur H. Prophylaxis of Mycobacterium avium complex bacteremia in patients with AIDS. Clin Infect Dis 1994; 18 Suppl. 3: S223–6

    Article  PubMed  Google Scholar 

  4. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. MMWR 1993; 42(RR-9): 17–20

    Google Scholar 

  5. Brogden RN, Fitton A. Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 983–1009

    Article  PubMed  CAS  Google Scholar 

  6. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. N Engl J Med 1993; 329: 828–33

    Article  PubMed  CAS  Google Scholar 

  7. British National Formulary No. 27. London: The Pharmaceutical Press, 1994; 302

  8. Sullam PM, Gordin FM, Wynne BA, et al. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin Infect Dis 1994; 19: 84–6

    Article  PubMed  CAS  Google Scholar 

  9. Committee of Safety of Medicines. Rifabutin (Mycobutin) uveitis. Curr Probl Pharmacovigilance 1994; 20: 4

    Google Scholar 

  10. Uveitis associated with rifabutin therapy. MMWR 1994; 43: 658

  11. Shafran SD, Deschênes J, Miller M, et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin and ethambutol [correspondence]. N Engl J Med 1994; 330: 438–9

    Article  PubMed  CAS  Google Scholar 

  12. Havlir D, Torriani F, Dubé M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med 1994; 121: 510–2

    PubMed  CAS  Google Scholar 

  13. Saran BR, Maguire AM, Nichols C, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994; 112: 1159–65

    Article  PubMed  CAS  Google Scholar 

  14. Grange JM, Winstanley PA, Davies PDO. Clinically significant drug interactions with antituberculosis agents. Drug Saf 1994; 11: 242–51

    Article  PubMed  CAS  Google Scholar 

  15. Physicians GenRx. New York: Data Pharmaceutica Inc., 1994: 1963–5

  16. DATRI 001 Study Group. Coadministration of clarithromycin alters the concentration-time profile of rifabutin [abstract]. Abstracts of the 34th Int Conf Antimicrob Ag Chemother 1994

  17. Rifabutin prophylaxis against Mycobacterium avium complex infection [correspondence]. N Engl J Med 1994; 330: 436–8

  18. Revicki DA, Simpson KN, Wu AW, et al. Quality of life in rifabutin prophylaxis for Mycobacterium avium complex in people with AIDS [abstract]. Qual Life Res 1994; 3: 44

    Google Scholar 

  19. Pachucki CT, Lentino JR, Mullane K, et al. To use rifabutin prophylaxis or to diagnose disseminated Mycobacterium avium complex (dMAC) infections earlier [abstract]. Clin Infect Dis 1994; 19: 642

    Google Scholar 

  20. Rifabutin. Presc Int 1994; 3: 130–2

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rifabutin prophylaxis against MAC infections. Drugs Ther. Perspect 5, 1–4 (1995). https://doi.org/10.2165/00042310-199505020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505020-00001

Keywords

Search

Navigation